-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer -BioNTech BNT162b2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (HSCT) recipients of immune immunogenicity and safety is not clear
Pfizer -BioNTech BNT162b2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (HSCT) recipients of immune immunogenicity and safety is not clear
Security, security, safety
No serious adverse events (AE) related to vaccines were observed in the study
Adverse event (AE) P
Immunogenicity of BNT162b2 after vaccination
Immunogenicity of BNT162b2 after vaccinationAt a median time of 28 days (IQR 8-69) after the second vaccination, 118 patients (77·6%) developed RBD IgG with a GMT of 2.
P P
Multivariate logistic regression model of RBD IgG positivity between HSCT recipients and immune normal controls (n= 424)
Multivariate logistic regression model of RBD IgG positivity between HSCT recipients and immune normal controls (n= 424)
CI, confidence interval; HSCT, hematopoietic stem cell transplantation; IgG, immunoglobulin G; RBD, receptor binding domain
IgG quantification after the second vaccination of BNT162b2 vaccine in HSCT recipients and immunocompetent medical staff controls
IgG quantification after the second vaccination of BNT162b2 vaccine in HSCT recipients and immunocompetent medical staff controls
The study found that there is a high correlation between RBD binding IgG and NA, r= 0·70 (95% CI 0·59, 0·78; P<0·0001) (Figure2 ) r P (Figure2 )
Correlation between RBD IgG and logarithmic transformed neutralizing antibodies
Correlation between RBD IgG and logarithmic transformed neutralizing antibodies
After the second vaccination, no patients in the cohort were infected with SARS-CoV-2, and the median follow-up time was 108 (104-114) days
In summary, the BNT162b2 mRNA vaccine is safe and effective in HSCT recipients, especially those without immunosuppression
Original source:
Shem-Tov, N.
Shem-Tov, N.
Leave a message here